GILD Financials Gilead Sciences

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 41 d ago Overview →

Growth & profitability

Revenue has grown 3.6% per year over the past 5 years.
Net income has grown faster than revenue (133.3% vs 3.6% per year).
Operating margin has expanded, at 34.0% in the latest year.
Free cash flow has grown 4.7% per year over the past 5 years.

Financial health

Total debt ($24.9B) exceeds cash ($7.6B); net debt is $17.4B.
Total debt has grown slower than revenue (-4.5% vs 3.6% per year).
Operating income covered interest expense 9.8× in the latest year.
Total debt is 2.5× EBITDA.

Shareholder returns

Dividends have been paid for 11 consecutive years, consuming 47.0% of earnings and 42.3% of free cash flow.
The dividend has grown 3.0% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$29.4B	$8.5B	78.8%	34.0%	37.5%	14.4%	$9.5B	$24.9B	$7.6B
2024	$28.8B	$480M	78.3%	5.8%	2.5%	0.8%	$10.3B	$26.7B	$10.0B
2023	$27.1B	$5.7B	76.0%	28.0%	24.8%	9.1%	$7.4B	$25.0B	$6.1B
2022	$27.3B	$4.6B	79.3%	26.9%	21.6%	7.3%	$8.3B	$25.2B	$5.4B
2021	$27.3B	$6.2B	75.8%	36.3%	29.5%	9.2%	$10.8B	$26.7B	$5.3B
2020	$24.7B	$123M	81.5%	16.5%	0.7%	0.2%	$7.5B	$31.4B	$6.0B
2019	$22.4B	$5.4B	79.2%	19.1%	23.9%	8.7%	$8.3B	$24.6B	$11.6B
2018	$22.1B	$5.5B	78.1%	37.1%	25.5%	8.6%	$7.5B	$27.3B	$17.9B
2017	$26.1B	$4.6B	83.3%	54.1%	22.6%	6.6%	—	$33.5B	$7.6B
2016	$30.4B	$13.5B	86.0%	58.0%	71.5%	23.7%	—	$26.3B	$8.2B
2015	—	$18.1B	—	—	97.7%	35.0%	—	$22.1B	—
2014	—	$12.1B	—	—	78.4%	34.9%	—	$12.4B	—
2013	—	$3.1B	—	—	27.0%	13.6%	$3.0B	$6.6B	—
2012	—	$2.6B	—	—	27.9%	12.2%	—	$8.2B	—
2011	—	$2.8B	—	—	41.6%	16.2%	—	$7.6B	—

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$7.8B	-$10.5B	79.8%	-133.2%	-88.7%	-21.3%	$3.4B	$26.2B	$3.2B
Mar '26	$7.0B	$2.0B	79.2%	37.2%	8.6%	3.6%	$2.4B	$22.2B	$7.6B
Dec '25	$7.9B	$2.2B	79.5%	25.0%	9.6%	3.7%	$3.1B	$24.9B	$7.6B
Sep '25	$7.8B	$3.1B	79.8%	42.8%	14.2%	5.2%	$4.0B	$24.9B	$7.3B
Jun '25	$7.1B	$2.0B	78.8%	34.9%	10.0%	3.5%	$720M	$24.9B	$5.1B
Mar '25	$6.7B	$1.3B	76.9%	33.6%	6.9%	2.3%	$1.7B	$25.0B	$7.9B
Dec '24	$7.6B	$1.8B	79.1%	32.4%	9.2%	3.0%	$2.8B	$26.7B	$10.0B
Sep '24	$7.5B	$1.3B	79.1%	11.8%	6.8%	2.3%	$4.2B	$23.2B	$5.0B
Jun '24	$7.0B	$1.6B	77.8%	38.0%	8.8%	3.0%	$1.2B	$23.3B	$2.8B
Mar '24	$6.7B	-$4.2B	76.8%	-64.6%	-23.8%	-7.4%	$2.1B	$25.2B	$4.7B
Dec '23	$7.1B	$1.4B	70.6%	22.7%	6.3%	2.3%	$2.0B	$25.0B	$6.1B
Sep '23	$7.1B	$2.2B	77.8%	37.2%	9.8%	3.5%	$1.6B	$25.0B	$5.7B
Jun '23	$6.6B	$1.0B	78.1%	25.2%	4.9%	1.7%	$2.2B	$25.2B	$5.7B
Mar '23	$6.4B	$1.0B	77.9%	26.8%	4.8%	1.6%	$1.6B	$25.2B	$4.9B
Dec '22	$7.4B	$1.6B	81.1%	30.7%	7.7%	2.6%	$2.4B	$25.2B	$5.4B
Sep '22	$7.0B	$1.8B	80.2%	40.3%	8.5%	2.9%	$2.7B	$25.2B	$4.7B
Jun '22	$6.3B	$1.1B	77.0%	32.4%	5.7%	1.8%	$1.7B	$26.2B	$4.7B
Mar '22	$6.6B	$19M	78.4%	3.0%	0.1%	0.0%	$1.6B	$26.2B	$4.3B
Dec '21	$7.2B	$382M	63.7%	13.0%	1.8%	0.6%	$3.0B	$26.7B	$5.3B
Sep '21	$7.4B	$2.6B	83.5%	51.8%	12.1%	3.9%	$3.1B	$27.7B	$4.4B

Valuation over time

How the market has priced GILD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 22.4× (Mar '23) to 22.0× (Sep '26).
The price-to-sales ratio has risen from 3.8× (Mar '23) to 6.4× (Sep '26).
The dividend yield has fallen from 3.6% (Mar '23) to 2.1% (Sep '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is GILD growing its revenue and profit?

Over the past 5 years, Gilead Sciences's revenue has grown 3.6% per year, and net income grown 133.3% per year. These are computed facts, not advice.

How much debt does GILD have?

As of FY2025, Gilead Sciences reported $24.9B of total debt against $7.6B of cash; operating income covered interest expense 9.8×.

What is GILD's profit margin?

In FY2025, gross margin was 78.8%, operating margin 34.0%, and net margin 28.9%.

What is GILD's P/E ratio?

As of Sep '26, Gilead Sciences traded at a price-to-earnings ratio of about 22.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.